[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537164":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":33,"responsibleParty":56,"collaborators":58,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":20,"enrollmentInfo":71,"targetDuration":20,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":20,"overallStatus":35,"whyStopped":20,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Centre Hospitalier Metropole Savoie","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Interventionnal","EXPERIMENTAL","\"Hand Grip\" Dynamometer Chair rise test measurement of impedance SEFI Nutritional Intake Assessment Questionnaire GPAQ questionnaire SARC-F questionnaire",[13],"Diagnostic Test: Sarcopenia diagnostic test",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Sarcopenia diagnostic test","the study-specific measurements for the assessment of sarcopenia (impedancemetry, grip strength and chair rise test) as well as the distribution of actimeters to patients.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Aurelie FILLON","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","04.79.96.58.13","aurelie.fillon@ch-metropole-savoie.fr",{"name":31,"role":27,"phone":28,"phoneExt":20,"email":32},"Nathalie MARQUES, Dr","nathalie.marques@ch-metropole-savoie.fr",[34],{"facility":5,"status":35,"city":36,"state":20,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Chambéry","73000","France","FR",{"type":41,"coordinates":42},"Point",[43,44],5.92079,45.56628,{"lat":44,"lon":43},[47,49,52,53],{"name":48,"role":27,"phone":28,"phoneExt":20,"email":29},"aurelie fillon",{"name":50,"role":27,"phone":28,"phoneExt":20,"email":51},"florence jego","florence.jego@ch-metropole-savoie.fr",{"name":48,"role":24,"phone":20,"phoneExt":20,"email":20},{"name":54,"role":55,"phone":20,"phoneExt":20,"email":20},"nathalie marques","SUB_INVESTIGATOR",{"type":57,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[59],{"name":60,"class":6},"Université Savoie Mont Blanc","100537164","effect-of-sarcopenia-on-the-occurrence-of-toxicity-related-to-anti-cancer-treatments-100537164",false,"NCT06274268","Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments","Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments. Prospective Cohort Study","SARC-ONCO","Inclusion Criteria:\n\n* Patients over 18 years old\n* Patient with a diagnosis of a histologically proven solid malignant tumor with an indication for systemic treatment during initial treatment.\n* CT\u002FPET performed within 45 days before initiation of systemic treatment.\n* Patient able to sign informed consent for participation in the study\n* Patient affiliated to a social security system\n\nExclusion Criteria:\n\n* History of cancer in the five years preceding inclusion other than localized skin or cervical cancers.\n* Patient with cancer not requiring systemic treatment.\n* Pregnant women.\n* Patient with a pace maker or defibrillator\n* Patient deprived of liberty or benefiting from a legal protection measure","ALL","18 Years",{"count":72,"type":73},700,"ESTIMATED","INTERVENTIONAL",[76],"NA","The goal of this clinical trial is to learn about the effect of sarcopenic status on the occurrence of treatment-related toxicity during the first course of anti-cancer treatment in several types of cancers.\n\nThe main question it aims to answer is :\n\nIs sarcopenia a predictive marker for the occurrence of toxicity in the initial phase of cancer treatment?\n\nThe evaluation will focus on the body composition of the participants, assessed by impedancemetry, and on their muscular performance by standardized physical tests.",[79,80,81,82],"Sarcopenia","Oncology","Physical Inactivity","Toxicity Due to Chemotherapy","2024-07-17",{"date":85,"type":86},"2024-07-18","ACTUAL",{"date":88,"type":86},"2024-06-24",{"date":90,"type":73},"2028-05-01",{"name":5,"class":6},1]